Merck & Co., Inc: Leukemia trials
The registry lists 10 Leukemia studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 6Phase 2 5No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)CompletedNCT02663622Phase 2Results posted
- Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)CompletedNCT01254318Results posted
- Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)CompletedNCT00479232Phase 1Results posted
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic MalignanciesCompletedNCT00825487Phase 1
- A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)TerminatedNCT00405054Phase 2
- A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)TerminatedNCT00100152Phase 1
- Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)CompletedNCT00086125Phase 2
- Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)CompletedNCT00034684Phase 1/2